| |
Year:
1998
| Volume: 6
| Issue: 2
| Pages: 63-65
|
| |
Original Article |
| |
EFFECTS OF SOMATOSTATIN ANALOG (OCTREOTIDE) IN PATIENTS WITH STOMACH CANCER: ANALYSIS OF TWO GROWTH FACTORS
George ZAFIRIOU, George BLATZAS, Grammati GALAKTIDOU, Anna EFKARPIDOU, Alexandros H. KORTSARIS |
| |
DOI:
|
| |
Abstract: |
| |
Background: The goal of this work was the study of the effects of somatostatin-octreotide, in patients with stomach cancer. The decrease of post-operative pancreatitis, the number of ruptures of the anastomosis and the decrease of bleeding as well, were the major expected results of somatostatin activity. The measurement of the epidermal growth factor (EGF) and insulin like growth factor ( ILGF-1) were evaluated in correlation with the objective and subjective clinical aspects of the patients.
Methods: Forty five patients with stomach cancer were admitted to our Cancer Institute in Thessaloniki, between 1995-1996, and enrolled in a protocol which involved somatostatin. Twenty four of these patients were administered with 0.1 mg Sandostatin subcutaneously (sc) three times a day for 7 days. The levels of the two growth factors were estimated three times.
Results: The observations obtained show an analgesic effect of the somatostatin while there were no significant differences in pancreatitis or in other clinical aspects. The results show a good correlation between the clinical findings and the levels of the growth factors.
Conclusion: The results obtained confirm the beneficial effects of somatostatin in patients with stomach cancer. A further investigation with a larger number of patients could be of great interest. The relation of these effects with the levels of the two growth factors suggests that these two parameters could be used as markers. |
| |
Key words:
Somatostatin; Stomach cancer; Growth factors |
| |
Read
full text in PDF [Full
Text] |
|
|